Hepatitis B vaccine in infants from an endemic area: Long-term anti-HBs persistence and revaccination

✍ Scribed by B. Yvonnet; P. Coursaget; J. Chotard; M. Sarr; R. Ndoye; J. P. Chiron; I. Diop-Mar

• Publisher: John Wiley and Sons
• Year: 1987
• Tongue: English
• Weight: 395 KB
• Volume: 22
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/jmv.1890220404

✦ Synopsis

Persistence of anti-HBs in 156 Senegalese infants immunized with hepatitis B vaccine was studied for periods ranging from 2 to 6 years after booster dose administration. Six years after the booster dose, 90.4% of the infants had detectable anti-HBs antibodies, with 78.1% having titers higher than 10 mIU/ml. The geometric mean titer was 60 mIU/ml. Females showed higher anti-HBs values than males. In a group of 11 infants who received no booster dose, anti-HBs antibodies were detectable 7 years after the first dose. However, the geometric mean titer was lower (26 mIU/ml). Revaccination (56 infants) led to an increase of the geometric mean titer to 469 mIU/ml 2 months later. These results show that a booster injection every 5-6 years should provide adequate protective anti-HBs levels in infants.